Literature DB >> 18958441

[Restless legs syndrome, periodic limb movements, and psychopharmacology].

S Cohrs1, A Rodenbeck, M Hornyak, D Kunz.   

Abstract

Restless legs syndrome (RLS) and the often associated periodic limb movement disorder in sleep (PLMD) frequently occur in the general population as a primary disorder. In addition to organic disease, secondary forms are caused by psychotropic medication. Several antidepressants, antipsychotics, lithium, and opioid withdrawal have been shown to induce or exacerbate RLS and PLMD, while several antiepileptics used as mood stabilizers and some benzodiazepines demonstrate therapeutic potential for treating RLS/PLMD. Systematic or controlled studies for evaluating these side effects still do not exist. Among the antidepressants at higher risk of inducing this disorder are selective serotonin reuptake inhibitors, venlafaxine, and some tetracyclic antidepressants. Under medication with some tricyclic substances, periodic limb movements were observed more often. For some antidepressants with differing transmitter profiles such as bupropion RLS/PLMD ameliorating effects or at least neutral effects (Trazodon, Nortriptylin) have been described in small studies. In case of continued of or newly occurring insomnia a thorough history should be taken to identify a possible RLS/PLMD as an intolerable side effect of treatment. A change in medications should be considered if clinically feasible. In case of RLS/PLMD occurring in psychotic patients switching the antipsychotic and additionally using a second line medication such as antiepileptics or a benzodiazepine should be considered.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18958441     DOI: 10.1007/s00115-008-2575-2

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  81 in total

1.  Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients.

Authors: 
Journal:  Sleep Med       Date:  2001-01       Impact factor: 3.492

2.  Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine.

Authors:  T Kraus; A Schuld; T Pollmächer
Journal:  J Clin Psychopharmacol       Date:  1999-10       Impact factor: 3.153

3.  Mirtazapine may have the propensity for developing a restless legs syndrome? A case report.

Authors:  Won-Myong Bahk; Chi-Un Pae; Jeong-Ho Chae; Tae-Youn Jun; Kwang-Soo Kim
Journal:  Psychiatry Clin Neurosci       Date:  2002-04       Impact factor: 5.188

4.  Bupropion may improve restless legs syndrome: a report of three cases.

Authors:  Sung-Wan Kim; Il-Seon Shin; Jae-Min Kim; Su-Jin Yang; Hee-Young Shin; Jin-Sang Yoon
Journal:  Clin Neuropharmacol       Date:  2005 Nov-Dec       Impact factor: 1.592

5.  Longitudinal effects of nortriptyline on EEG sleep and the likelihood of recurrence in elderly depressed patients.

Authors:  D J Buysse; C F Reynolds; C C Hoch; P R Houck; D J Kupfer; S Mazumdar; E Frank
Journal:  Neuropsychopharmacology       Date:  1996-04       Impact factor: 7.853

6.  Restless legs syndrome probably induced by risperidone treatment.

Authors:  T C Wetter; J Brunner; T Bronisch
Journal:  Pharmacopsychiatry       Date:  2002-05       Impact factor: 5.788

7.  Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome.

Authors:  Svenja Happe; Cornelia Sauter; Gerhard Klösch; Bernd Saletu; Josef Zeitlhofer
Journal:  Neuropsychobiology       Date:  2003       Impact factor: 2.328

8.  Nitrazepam for periodic movements in sleep (sleep-related myoclonus).

Authors:  H Moldofsky; C Tullis; G Quance; F A Lue
Journal:  Can J Neurol Sci       Date:  1986-02       Impact factor: 2.104

9.  Sleep-promoting properties of quetiapine in healthy subjects.

Authors:  Stefan Cohrs; Andrea Rodenbeck; Zhenghua Guan; Kathrin Pohlmann; Wolfgang Jordan; Andreas Meier; Eckart Rüther
Journal:  Psychopharmacology (Berl)       Date:  2004-03-17       Impact factor: 4.530

10.  Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid.

Authors:  Ilonka Eisensehr; Bruce L Ehrenberg; Silvia Rogge Solti; Soheyl Noachtar
Journal:  J Neurol       Date:  2004-05       Impact factor: 4.849

View more
  5 in total

1.  Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study.

Authors:  Heike Benes; Wolfgang Mattern; Ines Peglau; Tillmann Dreykluft; Lars Bergmann; Corinna Hansen; Ralf Kohnen; Norbert Banik; S W Schoen; Magdolna Hornyak
Journal:  J Neurol       Date:  2010-12-28       Impact factor: 4.849

Review 2.  Sleep-dependent memory consolidation and its implications for psychiatry.

Authors:  Monique Goerke; Notger G Müller; Stefan Cohrs
Journal:  J Neural Transm (Vienna)       Date:  2015-10-30       Impact factor: 3.575

3.  The Role of Pharmacogenetic Testing in the Amelioration of Antidepressant-Related Motor Disturbances in 2 Young Adult Men With Major Depressive Disorder.

Authors:  Karen H Rhea; William M Petrie; Kathryn R Gardner
Journal:  Prim Care Companion CNS Disord       Date:  2015-01-08

4.  Psychiatric comorbidity in children and adolescents with restless legs syndrome: a retrospective study.

Authors:  Samuel J Pullen; Christopher A Wall; Elizabeth R Angstman; Gillian E Munitz; Suresh Kotagal
Journal:  J Clin Sleep Med       Date:  2011-12-15       Impact factor: 4.062

5.  Depressive disorders in restless legs syndrome: epidemiology, pathophysiology and management.

Authors:  Magdolna Hornyak
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.